• Publications
  • Influence
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
TLDR
Axitinib is a treatment option for second-line therapy of advanced renal cell carcinoma and resulted in significantly longer progression-free survival (PFS) compared with sorafenib. Expand
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
TLDR
This model validates components of the MSKCC model with the addition of platelet and neutrophil counts and can be incorporated into patient care and into clinical trials that use VEGF-targeted agents. Expand
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma
TLDR
Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate‐ and poor‐risk patients with previously untreated advanced renal‐cell carcinoma. Expand
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.
TLDR
The genetics of RCC and these promising clinical results support the hypothesis that VEGF and PDGF receptor-mediated signaling is an effective therapeutic target in RCC, as second-line therapy in a setting where no effective systemic therapy is presently recognized. Expand
Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
TLDR
Sunitinib-based therapy has the potential to modulate antitumor immunity by reversing MDSC-mediated tumor-induced immunosuppression and is correlated with reversal of type 1 T-cell suppression. Expand
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma
TLDR
Treatment with pembrolizumab plus axitinib resulted in significantly longer overall survival and progression‐free survival, as well as a higher objective response rate, than treatment with sunitin ib among patients with previously untreated advanced renal‐cell carcinoma. Expand
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.
TLDR
Nivolumab demonstrated antitumor activity with a manageable safety profile across the three doses studied in mRCC, and no dose-response relationship was detected as measured by PFS. Expand
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
TLDR
The outcomes of a cohort of patients with cancer and COVID-19 are characterised and potential prognostic factors for mortality and severe illness are identified and race and ethnicity, obesity status, cancer type, type of anticancer therapy, and recent surgery were not associated with mortality. Expand
Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma
TLDR
Progression‐free survival was significantly longer with avelumab plus axitinib than with sunit inib among patients who received these agents as first‐line treatment for advanced renal‐cell carcinoma. Expand
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.
TLDR
Patients who developed HTN on bevacizumab plus IFN-alpha had a significantly improved PFS and OS versus patients without HTN, and HTN may be a biomarker of outcome with bevaccizumAB plus IFn-alpha. Expand
...
1
2
3
4
5
...